Antihypertensive drugs angiotensin antagonists

A closely related reaction that is currently receiving much attention is the palladium-catalysed Suzuki coupling of arylboronic acids with aryl halides (Fu and Littke, 1998). For example, this technology has recently been applied by Clariant workers for the production of o-tolyl-benzonitrile (Eqn. (13)), an intermediate to a series of so-called angiotensin-II antagonists, a new class of antihypertensive drugs (Bernhagen, 1998). 

ALISKIREN ANTIHYPERTENSIVES AND HEART FAILURE DRUGS-ANGIOTENSIN II RECEPTOR ANTAGONISTS Aliskiren levels possibly 1 by irbesartan. Risk of hyperkalaemia Uncertain Monitor BP at least weekly until stable... 

The only receptor-targeted antihypertensive drugs in the renin-angiotensin system (RAS) are the antagonists of the angiotensin II (ATI) receptor. 

Angiotensin-II-receptor antagonists (ARBs) are approved for the treatment of hypertension. In addition, irbesartan and losartan are approved for diabetic nephropathy, losar-tan is approved for stroke prophylaxis, and valsartan is approved for heart failure patients who are intolerant of angiotensin-converting enzyme (ACE) inhibitors. The efficacy of ARBs in lowering blood pressure (BP) is comparable with that of other established antihypertensive drugs, with an adverse-effect profile similar to that of placebo. ARBs also are available as fixed-dose combinations with hydrochlorothiazide. 

Epoetin may cause hypertension and thereby reduce the effects of antihypertensive drugs. An additive hyperkalaemic effect is theoretically possible with ACE inhibitors or angiotensin II receptor antagonists and epoetin. It is not entirely clear whether captopril, enalapril, fosinopril or other ACE inhibitors affect the efficacy of epoetin or not, but any interaction may take many months to develop. 

---